Glenmark Pharmaceuticals to Launch DCGI-approved BRUKINSA in India for Hematological Malignancies Treatment
Glenmark Pharmaceuticals Ltd. has announced the upcoming launch of zanubrutinib in India, marketed under the brand name BRUKINSA®. The drug is approved by the DCGI for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). BRUKINSA is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved in India for these malignancies, with compelling clinical evidence from pivotal trials. The introduction of BRUKINSA addresses a critical unmet need, demonstrating high response rates and durable disease control across multiple B-cell malignancies.
Key Highlights
- Glenmark Pharmaceuticals to launch BRUKINSA in India, a DCGI-approved therapy for hematological malignancies.
- BRUKINSA is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved in India for five distinct B-cell malignancies.
- BRUKINSA has demonstrated high response rates and durable disease control across multiple B-cell malignancies in pivotal trials.
- The launch of BRUKINSA addresses a critical unmet need in India's healthcare sector.
- BRUKINSA has a differentiated pharmacological profile and a flexible dosing regimen.